Hall Laurie J Trustee decreased its holdings in AbbVie Inc (NYSE:ABBV) by 0.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,195 shares of the company’s stock after selling 250 shares during the quarter. AbbVie accounts for about 2.4% of Hall Laurie J Trustee’s holdings, making the stock its 11th biggest holding. Hall Laurie J Trustee’s holdings in AbbVie were worth $3,785,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. RNC Capital Management LLC boosted its stake in shares of AbbVie by 2.6% in the second quarter. RNC Capital Management LLC now owns 701,326 shares of the company’s stock valued at $50,853,000 after purchasing an additional 17,865 shares during the period. Atlantic Trust LLC raised its holdings in AbbVie by 208.4% in the second quarter. Atlantic Trust LLC now owns 2,467 shares of the company’s stock valued at $179,000 after acquiring an additional 1,667 shares in the last quarter. WFG Advisors LP raised its holdings in AbbVie by 22.0% in the second quarter. WFG Advisors LP now owns 37,131 shares of the company’s stock valued at $2,692,000 after acquiring an additional 6,695 shares in the last quarter. Toronto Dominion Bank raised its holdings in AbbVie by 17.0% in the second quarter. Toronto Dominion Bank now owns 589,937 shares of the company’s stock valued at $42,774,000 after acquiring an additional 85,876 shares in the last quarter. Finally, Oak Associates Ltd. OH acquired a new stake in AbbVie in the second quarter valued at approximately $358,000. 69.32% of the stock is owned by institutional investors and hedge funds.

Shares of AbbVie Inc (ABBV) opened at $96.30 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 1-year low of $59.27 and a 1-year high of $98.87. The firm has a market cap of $155,412.45, a P/E ratio of 18.33, a price-to-earnings-growth ratio of 1.35 and a beta of 1.52.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.02. The business had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The company’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the firm posted $1.21 earnings per share. sell-side analysts expect that AbbVie Inc will post 5.55 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.71 per share. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.95%. AbbVie’s dividend payout ratio (DPR) is 62.29%.

ABBV has been the topic of several analyst reports. Jefferies Group raised their target price on shares of AbbVie from $107.00 to $115.00 and gave the company a “buy” rating in a report on Monday, October 16th. BMO Capital Markets set a $66.00 target price on shares of AbbVie and gave the company a “hold” rating in a report on Friday, October 27th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. Piper Jaffray Companies raised their target price on shares of AbbVie to $115.00 and gave the company an “overweight” rating in a report on Friday, October 27th. Finally, SunTrust Banks reaffirmed a “buy” rating on shares of AbbVie in a report on Monday, October 30th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $97.96.

In other news, VP Robert A. Michael sold 6,699 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $88.00, for a total transaction of $589,512.00. Following the transaction, the vice president now directly owns 10,007 shares in the company, valued at $880,616. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Richard A. Gonzalez sold 218,193 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at $46,255,740.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 268,825 shares of company stock worth $25,186,090. Insiders own 0.23% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Hall Laurie J Trustee Sells 250 Shares of AbbVie Inc (ABBV)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/15/hall-laurie-j-trustee-sells-250-shares-of-abbvie-inc-abbv.html.

AbbVie Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related stocks with our FREE daily email newsletter.